

# 2025 ASCO<sup>®</sup> ANNUAL MEETING



**Dra. Nieves Martínez Lago**

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

## TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD LOCALMENTE AVANZADA

Resumen en vídeo

Resumen en texto

### MATTERHORN

**LBA 5. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).**

Ver Abstract

### CheckMate 577

**4000. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.**

Ver Abstract

### ESOPEC

**4014. Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.**

Ver Abstract



GRUPO DE TRATAMIENTO  
DE LOS TUMORES DIGESTIVOS

# 2025 ASCO<sup>®</sup> ANNUAL MEETING



**Dra. Nieves Martínez Lago**

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

## TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD METASTÁSICA HER2 POSITIVA

Resumen en vídeo

Resumen en texto

### DESTINY-Gastric04

**LBA 4002. Trastuzumab deruxtecan (T-DXd) vs. ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.**

[Ver Abstract](#)

### Abstract 4013

**4013. Long-term outcomes and overall survival for zanidatamab + chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma: 4-years follow-up of a phase II.**

[Ver Abstract](#)



GRUPO DE TRATAMIENTO  
DE LOS TUMORES DIGESTIVOS

# 2025 ASCO<sup>®</sup> ANNUAL MEETING



**Dra. Nieves Martínez Lago**

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

## TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD METASTÁSICA HER2 NEGATIVA

Resumen en vídeo

Resumen en texto

### LEAP-015

**4001. Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.**

Ver Abstract

### CT041-ST-01

**4003. Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).**

Ver Abstract



GRUPO DE TRATAMIENTO  
DE LOS TUMORES DIGESTIVOS